Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study

Laura Kranaster; Carolin Hoyer; Suna S. Aksay; J. Malte Bumb; Norbert Müller; Peter Zill; Markus J. Schwarz; Natalie Moll; Beat Lutz; Laura Bindila; Inga Zerr; Matthias Schmitz; Kaj Blennow; Henrik Zetterberg; Dieter Haffner; Maren Leifheit-Nestler; Cagakan Ozbalci; Christoph Janke; Manfred Thiel; Alexander Sartorius

doi:10.1159/000491401

Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study

Laura Kranaster, Carolin Hoyer, Suna S. Aksay, J. Malte Bumb, Norbert Müller, Peter Zill, Markus J. Schwarz, Natalie Moll, Beat Lutz, Laura Bindila, Inga Zerr, Matthias Schmitz, Kaj Blennow, Henrik Zetterberg, Dieter Haffner, Maren Leifheit-Nestler, Cagakan Ozbalci, Christoph Janke, Manfred Thiel, Alexander Sartorius

Randall Centre of Cell & Molecular Biophysics

Research output: Contribution to journal › Article › peer-review

27 Citations (Scopus)

Abstract

Background: No candidate biomarkers based on cerebrospinal fluid (CSF) have been identified as prognostic factors in patients with major depression treated with electroconvulsive therapy (ECT), yet. Method: Following different underlying hypotheses, we analysed baseline CSF levels of markers of neurodegeneration (tau proteins, β-amyloids and neurogranin), elements of the innate immune system (interleukin [IL]-6, neopterin, soluble CD14, soluble CD163, migration inhibitory factor and monocyte chemotactic protein 1), endocannabinoids, sphingolipids and Klotho before ECT in patients with depression (n = 12) to identify possible correlations with the clinical antidepressant response to ECT. Results: Correlation with the reduction of the depressive symptoms could be observed especially for markers of neurodegeneration and elements of the innate immune system. Differences for CSF levels of several markers were found between the groups of responders and non-responders at the trend level. Limitations: The sample size is small and the -distribution of responders and non-responders is uneven. Conclusions: It is this first study on CSF biomarkers for antidepressant efficacy of ECT warrants further research regarding the mechanism of ECT and personalized antidepressant therapy.

Original language	English
Journal	Neuropsychobiology
Early online date	17 Aug 2018
DOIs	https://doi.org/10.1159/000491401
Publication status	E-pub ahead of print - 17 Aug 2018

Keywords

Biomarker
Cerebrospinal fluid
Depression
Electroconvulsive therapy

Access to Document

10.1159/000491401

Cite this

Kranaster, L., Hoyer, C., Aksay, S. S., Bumb, J. M., Müller, N., Zill, P., Schwarz, M. J., Moll, N., Lutz, B., Bindila, L., Zerr, I., Schmitz, M., Blennow, K., Zetterberg, H., Haffner, D., Leifheit-Nestler, M., Ozbalci, C., Janke, C., Thiel, M., & Sartorius, A. (2018). Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study. Neuropsychobiology. Advance online publication. https://doi.org/10.1159/000491401

@article{6c538190ffd644d093b1b0076cf42eee,

title = "Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study",

abstract = "Background: No candidate biomarkers based on cerebrospinal fluid (CSF) have been identified as prognostic factors in patients with major depression treated with electroconvulsive therapy (ECT), yet. Method: Following different underlying hypotheses, we analysed baseline CSF levels of markers of neurodegeneration (tau proteins, β-amyloids and neurogranin), elements of the innate immune system (interleukin [IL]-6, neopterin, soluble CD14, soluble CD163, migration inhibitory factor and monocyte chemotactic protein 1), endocannabinoids, sphingolipids and Klotho before ECT in patients with depression (n = 12) to identify possible correlations with the clinical antidepressant response to ECT. Results: Correlation with the reduction of the depressive symptoms could be observed especially for markers of neurodegeneration and elements of the innate immune system. Differences for CSF levels of several markers were found between the groups of responders and non-responders at the trend level. Limitations: The sample size is small and the -distribution of responders and non-responders is uneven. Conclusions: It is this first study on CSF biomarkers for antidepressant efficacy of ECT warrants further research regarding the mechanism of ECT and personalized antidepressant therapy.",

keywords = "Biomarker, Cerebrospinal fluid, Depression, Electroconvulsive therapy",

author = "Laura Kranaster and Carolin Hoyer and Aksay, {Suna S.} and Bumb, {J. Malte} and Norbert M{\"u}ller and Peter Zill and Schwarz, {Markus J.} and Natalie Moll and Beat Lutz and Laura Bindila and Inga Zerr and Matthias Schmitz and Kaj Blennow and Henrik Zetterberg and Dieter Haffner and Maren Leifheit-Nestler and Cagakan Ozbalci and Christoph Janke and Manfred Thiel and Alexander Sartorius",

year = "2018",

month = aug,

day = "17",

doi = "10.1159/000491401",

language = "English",

journal = "Neuropsychobiology",

issn = "0302-282X",

publisher = "S. Karger AG",

}

Kranaster, L, Hoyer, C, Aksay, SS, Bumb, JM, Müller, N, Zill, P, Schwarz, MJ, Moll, N, Lutz, B, Bindila, L, Zerr, I, Schmitz, M, Blennow, K, Zetterberg, H, Haffner, D, Leifheit-Nestler, M, Ozbalci, C, Janke, C, Thiel, M & Sartorius, A 2018, 'Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study', Neuropsychobiology. https://doi.org/10.1159/000491401

TY - JOUR

T1 - Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy

T2 - An Exploratory Cerebrospinal Fluid Study

AU - Kranaster, Laura

AU - Hoyer, Carolin

AU - Aksay, Suna S.

AU - Bumb, J. Malte

AU - Müller, Norbert

AU - Zill, Peter

AU - Schwarz, Markus J.

AU - Moll, Natalie

AU - Lutz, Beat

AU - Bindila, Laura

AU - Zerr, Inga

AU - Schmitz, Matthias

AU - Blennow, Kaj

AU - Zetterberg, Henrik

AU - Haffner, Dieter

AU - Leifheit-Nestler, Maren

AU - Ozbalci, Cagakan

AU - Janke, Christoph

AU - Thiel, Manfred

AU - Sartorius, Alexander

PY - 2018/8/17

Y1 - 2018/8/17

N2 - Background: No candidate biomarkers based on cerebrospinal fluid (CSF) have been identified as prognostic factors in patients with major depression treated with electroconvulsive therapy (ECT), yet. Method: Following different underlying hypotheses, we analysed baseline CSF levels of markers of neurodegeneration (tau proteins, β-amyloids and neurogranin), elements of the innate immune system (interleukin [IL]-6, neopterin, soluble CD14, soluble CD163, migration inhibitory factor and monocyte chemotactic protein 1), endocannabinoids, sphingolipids and Klotho before ECT in patients with depression (n = 12) to identify possible correlations with the clinical antidepressant response to ECT. Results: Correlation with the reduction of the depressive symptoms could be observed especially for markers of neurodegeneration and elements of the innate immune system. Differences for CSF levels of several markers were found between the groups of responders and non-responders at the trend level. Limitations: The sample size is small and the -distribution of responders and non-responders is uneven. Conclusions: It is this first study on CSF biomarkers for antidepressant efficacy of ECT warrants further research regarding the mechanism of ECT and personalized antidepressant therapy.

AB - Background: No candidate biomarkers based on cerebrospinal fluid (CSF) have been identified as prognostic factors in patients with major depression treated with electroconvulsive therapy (ECT), yet. Method: Following different underlying hypotheses, we analysed baseline CSF levels of markers of neurodegeneration (tau proteins, β-amyloids and neurogranin), elements of the innate immune system (interleukin [IL]-6, neopterin, soluble CD14, soluble CD163, migration inhibitory factor and monocyte chemotactic protein 1), endocannabinoids, sphingolipids and Klotho before ECT in patients with depression (n = 12) to identify possible correlations with the clinical antidepressant response to ECT. Results: Correlation with the reduction of the depressive symptoms could be observed especially for markers of neurodegeneration and elements of the innate immune system. Differences for CSF levels of several markers were found between the groups of responders and non-responders at the trend level. Limitations: The sample size is small and the -distribution of responders and non-responders is uneven. Conclusions: It is this first study on CSF biomarkers for antidepressant efficacy of ECT warrants further research regarding the mechanism of ECT and personalized antidepressant therapy.

KW - Biomarker

KW - Cerebrospinal fluid

KW - Depression

KW - Electroconvulsive therapy

UR - http://www.scopus.com/inward/record.url?scp=85052745561&partnerID=8YFLogxK

U2 - 10.1159/000491401

DO - 10.1159/000491401

M3 - Article

AN - SCOPUS:85052745561

SN - 0302-282X

JO - Neuropsychobiology

JF - Neuropsychobiology

ER -

Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this